^
Association details:
| Biomarker: | HER-2 exon 20 YVMA insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) + Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Published date:
10/15/2021
Excerpt:
HER2 exon 20 YVMA insertion tumors showed a potent and sustained response to the combination of mobocertinib and ado-trastuzumab emtansine (T-DM1).
DOI:
10.1158/0008-5472.CAN-21-1526
